---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Phase of product development"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Phase of product development. Topics: Regulatory status: Under review; NDA submitted in the third quarter of 2026, Commercial preparation for a potential U.S. launch, Investigational status, FDA agreement to review the NDA under the Real-Time Oncology Review program, and 19 further topics. 23 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Under review; NDA submitted in the third quarter of 2026

> “During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program.”
> “Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

> “In the third quarter of 2026, the Company completed the darovasertib mUM new drug application (“NDA”) submission to the FDA.”
> “Under the license agreement with Novartis, the Company paid a $2.0 million milestone payment.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “NDA filing completed in Q3’26”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Commercial preparation for a potential U.S. launch

> “We presented the positive topline results at ASCO from our registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic uveal melanoma while continuing to advance our NDA submission and pre-commercial activities to support a possible commercial launch.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “General and administrative expenses increased by $23.7 million, or 53%, during the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 primarily due to increases of $15.2 million in personnel-related expenses, including salaries, benefits and stock-based compensation, $4.8 million in commercial preparation activities for darovasertib, $3.1 million in audit, tax, consulting and other external services for continued company growth, and $0.6 million in legal expenses, including contracting and patent support.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “Darovasertib commercial readiness activities advancing in the United States and globally with their partner, Servier”

Source: [IDEAYA Biosciences press release, 2026 corporate objectives (2026)](https://media.ideayabio.com/2026-01-11-IDEAYA-Biosciences-Provides-a-Business-Update-and-Outlines-2026-Corporate-Objectives-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference)

<a id="topic-2.1.1-4"></a>

### Investigational status

> “Darovasertib is an investigational product and has not been approved by the FDA or any other regulatory authority.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

> “To date, none of the Company’s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-5"></a>

### FDA agreement to review the NDA under the Real-Time Oncology Review program

> “In April 2026, IDEAYA announced the U.S. Food and Drug Administration (FDA) has agreed to review their new drug application (NDA) for darovasertib in combination with crizotinib under the Oncology Center of Excellence Real-time Oncology Review (RTOR) program.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “The RTOR program is designed to enable a more efficient NDA submission and review process to make safe and effective treatments available to patients as early as possible.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-6"></a>

### FDA acceptance, priority review, and action date

No evidence found.

<a id="topic-2.1.1-7"></a>

### Accelerated approval on progression-free survival with overall survival for full approval

> “Based on our discussions with the U.S. Food and Drug Administration (FDA), the PFS data from OptimUM-02 may enable an accelerated approval filing in the United States.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Overall survival data, when available, will be used to support a potential full approval in the United States and globally.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “IDEAYA plans to provide an update on the OS data as part of the pre-specified interim analysis expected in mid-2027.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.1.1-8"></a>

### FDA orphan drug designation for uveal melanoma, April 2022

| Field | Quoted record |
| --- | --- |
| Generic name | “darovasertib” |
| Date designated | “04/27/2022” |
| Orphan designation | “Treatment of Uveal Melanoma” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “IDEAYA Biosciences Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=873322)

> “In April 2022, the FDA designated darovasertib as an Orphan Drug in UM, including primary and metastatic disease.”
> “If approved for one or more designated indications, darovasertib may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-9"></a>

### Fast Track designation for darovasertib with crizotinib in metastatic uveal melanoma, November 2022

> “In November 2022, the FDA granted Fast Track designation to our development program investigating darovasertib in combination with crizotinib in adult patients being treated for mUM.”
> “The Fast Track designation makes our darovasertib and crizotinib development program eligible for various expedited regulatory review processes, including generally more frequent FDA interactions, such as meetings and written communications, potential eligibility for rolling review and priority review of an NDA.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IDEAYA's development program investigating darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor, for the treatment of adult patients with metastatic uveal melanoma.”

Source: [IDEAYA Biosciences press release, Fast Track designation (2022)](https://media.ideayabio.com/2022-12-05-IDEAYA-Biosciences-Receives-Fast-Track-Designation-for-Darovasertib-Combination-Therapy-with-Crizotinib-for-the-Treatment-of-Metastatic-Uveal-Melanoma)

<a id="topic-2.1.1-10"></a>

### Breakthrough Therapy designation for neoadjuvant monotherapy in primary uveal melanoma, March 2025

> “In March 2025, the FDA granted Breakthrough Therapy designation (BTD) for darovasertib as a neoadjuvant treatment of adult patients with primary UM for whom enucleation has been recommended.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-11"></a>

### FDA designations as summarized by the company, October 2026

> “The U.S. Food and Drug Administration (FDA) has also granted darovasertib Fast Track designation for the treatment of metastatic uveal melanoma, Orphan Drug designation in primary uveal melanoma and Breakthrough Therapy Designation as a neoadjuvant therapy for patients with primary uveal melanoma for whom enucleation has been recommended.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-2.1.1-12"></a>

### European Union orphan designation for uveal melanoma, August 2025

> “This medicine was designated as an orphan medicine for the treatment of uveal melanoma in the European Union on 22 August 2025.”
> “The sponsorship was transferred to Les Laboratoires Servier.”

Source: [EMA orphan designation EU/3/25/3122 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3122)

<a id="topic-2.1.1-13"></a>

### Origin at Novartis and the 2018 license to IDEAYA

> “Herein, we describe the discovery of darovasertib (NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity.”
> “LXS196 is being investigated in the clinic as a monotherapy and in combination with other agents for the treatment of uveal melanoma (UM), including primary UM and metastatic uveal melanoma (MUM).”

Source: [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)

> “In September 2018, the Company entered into a License Agreement with Novartis to develop and commercialize Novartis’ LXS196 (also known as IDE196), a Phase 1 protein kinase C (“PKC”) inhibitor, for the treatment of cancers with GNAQ and GNA11 mutations.”
> “Under the license agreement, Novartis granted to the Company a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively referred to as the licensed products, for any purpose.”
> “The Company paid Novartis an upfront payment of $2.5 million and issued 263,615 shares of its Series B redeemable convertible preferred stock concurrently with the execution of the license agreement.”
> “The Company will also pay mid to high single-digit tiered royalty payments based on annual worldwide net sales of licensed products”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-14"></a>

### Servier license for rights outside the United States, August 2025

> “On August 29, 2025, IDEAYA Biosciences, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Les Laboratoires Servier (“Servier”) pursuant to which the Company granted to Servier an exclusive license under certain intellectual property rights controlled by the Company relating to darovasertib to develop and commercialize products in all countries worldwide except for the United States for all diagnostic, prophylactic and therapeutic uses in humans.”
> “Pursuant to the Agreement, Servier has agreed to provide the Company an upfront payment of $210 million.”
> “The Company is also eligible to receive development and regulatory milestone payments of up to an aggregate of $100 million, commercial milestone payments of up to an aggregate of $220 million, clinical trial cost sharing and clinical trial cost reimbursement, and royalties on net sales of products outside of the United States ranging from mid-teens to low-twenties percentages.”

Source: [IDEAYA Biosciences Form 8-K, Servier license agreement (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/d800731d8k.htm)

> “Servier will be responsible for the regulatory and commercial activities for darovasertib outside the United States.”
> “The Company and Servier will collaborate on the development of darovasertib and share the associated costs.”
> “The Company retains all rights to darovasertib in the United States.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-15"></a>

### Patent protection for darovasertib

> “These solely owned or in-licensed patent applications, if granted, would expire between 2035 and 2045, without taking into account any applicable patent term adjustments or extensions.”
> “In addition, the PKC program portfolio includes two U.S. patent application, which are jointly owned with Pfizer directed to methods of treatment for certain combination treatments.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-16"></a>

### Adjuvant setting: OptimUM-11 phase 3 trial of darovasertib with crizotinib, first participant dosed in September 2026

> “today announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary uveal melanoma who have completed local therapy and have an increased risk of developing metastatic disease.”
> “Patients will be eligible irrespective of HLA status and will be randomized 1:1 to receive darovasertib in combination with crizotinib for 12 months or observation.”
> “The primary endpoint of the trial is relapse-free survival.”
> “The companies will share the associated development costs of the trial.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

<a id="topic-2.1.1-17"></a>

### Neoadjuvant setting: closure of the OptimUM-10 phase 3 trial

> “Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial.”
> “This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892.”
> “IDEAYA is committed to enabling patient access to neoadjuvant darovasertib and plans to submit published data from OptimUM-09 to support potential inclusion in clinical practice guidelines.”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

<a id="topic-2.1.1-18"></a>

### Cash, cash runway, and financing

> “$1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

> “As of September 30, 2026, we had an accumulated deficit of $1,073.3 million.”
> “Based on our current business plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least the next 12 months from the issuance date of this Quarterly Report on Form 10-Q.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “In June, IDEAYA successfully completed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock, inclusive of the underwriters' full exercise of their option to purchase additional shares in the offering.”
> “Net proceeds from the offering were approximately $323.4 million, after deducting underwriting discounts, commissions and other expenses.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.1.1-19"></a>

### OptimUM-02 topline results reported in April 2026

> “On April 13th, IDEAYA reported positive topline data from the Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib in 1L HLA*A2-negative mUM.”

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program)

<a id="topic-2.1.1-20"></a>

### NDA submission in progress with completion expected in the second half of 2026, September and October 2026, superseded in November 2026

> “IDEAYA has initiated submission of a new drug application (NDA) for darovasertib in combination with crizotinib for patients with first line metastatic uveal melanoma (mUM) under the oncology center of excellence (OCE) real-time oncology review (RTOR) program and expects to complete the NDA submission in the second half of 2026.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

> “IDEAYA is submitting a new drug application (NDA) for darovasertib in combination with crizotinib for patients with first line metastatic uveal melanoma under the oncology center of excellence (OCE) real-time oncology review (RTOR) program and expects to complete the NDA submission in the second half of 2026.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-2.1.1-21"></a>

### Rolling NDA submission under RTOR with completion expected in the second half of 2026, April to August 2026, superseded in November 2026

> “IDEAYA plans to initiate the RTOR submission process with the first pre-submission targeted for May, with completion of the NDA filing expected in the second half of 2026.”

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program)

> “IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2 2026”

Source: [IDEAYA Biosciences press release, first quarter 2026 results (2026)](https://media.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “IDEAYA completed its first pre-submission in May and expects to complete the NDA filing in the second half of 2026.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.1.1-22"></a>

### NDA submission planned for the second half of 2026, April 2026, superseded in November 2026

> “NDA submission planned for H2'26 to support U.S. accelerated approval filing.”
> “Based on these data, the company will target to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-2.1.1-23"></a>

### OptimUM-02 topline results expected in the first quarter of 2026, January to March 2026, superseded in April 2026

> “Topline results, including progression free survival (PFS) data, from ongoing registrational Phase 2/3 OptimUM-02 trial of the darovasertib and crizotinib combination in first line (1L) patients with HLA*A2-negative metastatic UM (mUM) are expected in Q1 '26”

Source: [IDEAYA Biosciences press release, 2026 corporate objectives (2026)](https://media.ideayabio.com/2026-01-11-IDEAYA-Biosciences-Provides-a-Business-Update-and-Outlines-2026-Corporate-Objectives-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference)

> “Topline results, including progression free survival (PFS) data, from ongoing registrational Phase 2/3 OptimUM-02 trial of the darovasertib and crizotinib combination in first line (1L) patients with HLA*A2-negative metastatic UM are expected by approximately the last week of March, pending completion of ongoing data collection, cleaning and analysis.”
> “Topline PFS results, if positive, are anticipated to enable a potential accelerated approval filing in the United States.”

Source: [IDEAYA Biosciences press release, fourth quarter and full year 2025 results (2026)](https://media.ideayabio.com/2026-02-17-IDEAYA-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update)

> “We expect to report topline data, including progression free survival (PFS) data, from this trial in the first quarter of 2026.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Updated Topline Results Guidance: The database lock is projected in the first half of April, followed by the topline data analysis thereafter”

Source: [IDEAYA Biosciences press release, updated OptimUM-02 topline guidance (2026)](https://media.ideayabio.com/2026-03-22-IDEAYA-Biosciences-Upcoming-Investor-Relations-Events-and-Updated-Darovasertib-Topline-Results-Guidance-from-Phase-2-3-OptimUM-02-Trial)

<a id="topic-2.1.1-24"></a>

### Adjuvant setting: OptimUM-11 initiation planned for the first half of 2026 with a placebo comparator, February 2026, superseded in September 2026

> “We plan to initiate a global Phase 3 combination trial (OptimUM-11) of darovasertib and crizotinib in the adjuvant setting of primary UM in the first half of 2026.”
> “The trial is expected to enroll approximately 450 patients with high to medium-high risk of metastasis, randomized 1:1 to the combination of darovasertib and crizotinib or placebo.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-25"></a>

### Neoadjuvant setting: OptimUM-10 enrollment planned for completion in 2027, February and May 2026, superseded in November 2026

> “In 2025, we initiated a randomized Phase 3 trial of darovasertib in the neoadjuvant setting (OptimUM-10), which will enroll approximately 450 patients across two cohorts of plaque brachytherapy-eligible (PB) and enucleation-eligible (EN) patients.”
> “We plan to complete enrollment in this trial by the first half of 2027.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Full enrollment in the trial is estimated to be complete by the end of 2027, revised from prior guidance of first half of 2027.”

Source: [IDEAYA Biosciences press release, first quarter 2026 results (2026)](https://media.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
